Last reviewed · How we verify
NCT07156929: CICR-NAM_PK
Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation
NA trial testing Controlled-ileocolonic-release nicotinamide (CICR-NAM): 500 mg/d in Respiratory Infection (for Example, Pneumonia, Bronchitis) in 28 participants. Completed in 30 June 2025.
20 May 2025
Quick facts
| Lead sponsor | University Hospital Schleswig-Holstein |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 28 |
| Start date | 20 April 2024 |
| Primary completion | 20 May 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Controlled-ileocolonic-release nicotinamide (CICR-NAM): 500 mg/d
- Controlled-ileocolonic-release nicotinamide (CICR-NAM): 1000 mg/d
Conditions studied
- Respiratory Infection (for Example, Pneumonia, Bronchitis) — all drugs for Respiratory Infection (for Example, Pneumonia, Bronchitis) →
- Respiratory Infection Virus — all drugs for Respiratory Infection Virus →
- Community Acquired Pneumonia (CAP) — all drugs for Community Acquired Pneumonia (CAP) →
- COPD Acute Exacerbation — all drugs for COPD Acute Exacerbation →
Sponsor
University Hospital Schleswig-Holstein
Who can join
18 and older, any sex, with Respiratory Infection (for Example, Pneumonia, Bronchitis) or Respiratory Infection Virus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The diet of patients with reduced tryptophan serum levels that are either hospitalized for acute respiratory infection or treated for chronic inflammatory diseases such as inflammatory bowel diseases (in- or outpatients) is supplemented with controlled-ileocolonic-release nicotinamide (CICR-NAM) at doses of 500 mg or 1000 mg per day for four weeks. In the COVit-2 trial (NCT04751604), nicotinamide supplementation including CICR-NAM has been shown to accelerate physical recovery from mild-to-moderate COVID-19 (for publication, see References). The main objective of this open-label case series is to investigate the pharmacokinetics and metabolism of nicotinamide in patients with more severe respiratory infections or chronic inflammatory conditions. In addition, patients can optionally provide information on their quality of life and fatigue status.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07156929
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Respiratory Infection (for Example, Pneumonia, Bronchitis)
Currently open trials in the same condition.
- NCT07334795 — Intermountain Stewardship in Community Outpatient Settings-Resources & Engagement-Pediatrics · active not recruiting
- NCT05794815 — Modulation of Gut Microbiota by Probiotic in Children With Respiratory Symptoms · NA · recruiting
Other University Hospital Schleswig-Holstein trials
Trials by the same sponsor.
- NCT07591376 — A Reminder App to Improve Physical Activity During Radiotherapy for Lung Cancer - a Pre-study in Healthy Volunteers · NA · completed
- NCT07286747 — Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT) · Phase 2 · recruiting
- NCT07380815 — Physical Activity During Radiation Therapy for Lung Cancer · not yet recruiting
- NCT07148336 — Identification of Chemotherapy-induced Peripheral Neuropathy · NA · not yet recruiting
- NCT07444801 — Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07156929 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Schleswig-Holstein
- Last refreshed: 5 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07156929.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing